BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 19074846)

  • 1. Microsomal antiestrogen-binding site ligands induce growth control and differentiation of human breast cancer cells through the modulation of cholesterol metabolism.
    Payré B; de Medina P; Boubekeur N; Mhamdi L; Bertrand-Michel J; Tercé F; Fourquaux I; Goudounèche D; Record M; Poirot M; Silvente-Poirot S
    Mol Cancer Ther; 2008 Dec; 7(12):3707-18. PubMed ID: 19074846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular characterization of the microsomal tamoxifen binding site.
    Kedjouar B; de Médina P; Oulad-Abdelghani M; Payré B; Silvente-Poirot S; Favre G; Faye JC; Poirot M
    J Biol Chem; 2004 Aug; 279(32):34048-61. PubMed ID: 15175332
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Importance of cholesterol and oxysterols metabolism in the pharmacology of tamoxifen and other AEBS ligands.
    de Medina P; Paillasse MR; Ségala G; Khallouki F; Brillouet S; Dalenc F; Courbon F; Record M; Poirot M; Silvente-Poirot S
    Chem Phys Lipids; 2011 Sep; 164(6):432-7. PubMed ID: 21641337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ligands of the antiestrogen-binding site induce active cell death and autophagy in human breast cancer cells through the modulation of cholesterol metabolism.
    de Medina P; Payré B; Boubekeur N; Bertrand-Michel J; Tercé F; Silvente-Poirot S; Poirot M
    Cell Death Differ; 2009 Oct; 16(10):1372-84. PubMed ID: 19521424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification and pharmacological characterization of cholesterol-5,6-epoxide hydrolase as a target for tamoxifen and AEBS ligands.
    de Medina P; Paillasse MR; Segala G; Poirot M; Silvente-Poirot S
    Proc Natl Acad Sci U S A; 2010 Jul; 107(30):13520-5. PubMed ID: 20615952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 5,6-Epoxy-cholesterols contribute to the anticancer pharmacology of tamoxifen in breast cancer cells.
    Segala G; de Medina P; Iuliano L; Zerbinati C; Paillasse MR; Noguer E; Dalenc F; Payré B; Jordan VC; Record M; Silvente-Poirot S; Poirot M
    Biochem Pharmacol; 2013 Jul; 86(1):175-89. PubMed ID: 23500540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tamoxifen and AEBS ligands induced apoptosis and autophagy in breast cancer cells through the stimulation of sterol accumulation.
    de Medina P; Silvente-Poirot S; Poirot M
    Autophagy; 2009 Oct; 5(7):1066-7. PubMed ID: 19738414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improving the efficacy of hormone therapy in breast cancer: The role of cholesterol metabolism in SERM-mediated autophagy, cell differentiation and death.
    Leignadier J; Dalenc F; Poirot M; Silvente-Poirot S
    Biochem Pharmacol; 2017 Nov; 144():18-28. PubMed ID: 28642035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural similitudes between cytotoxic antiestrogen-binding site (AEBS) ligands and cytotoxic sigma receptor ligands. Evidence for a relationship between cytotoxicity and affinity for AEBS or sigma-2 receptor but not for sigma-1 receptor.
    Kedjouar B; Daunes S; Vilner BJ; Bowen WD; Klaebe A; Faye JC; Poirot M
    Biochem Pharmacol; 1999 Dec; 58(12):1927-39. PubMed ID: 10591147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiestrogen-binding site ligands induce autophagy in myeloma cells that proceeds through alteration of cholesterol metabolism.
    Sola B; Poirot M; de Medina P; Bustany S; Marsaud V; Silvente-Poirot S; Renoir JM
    Oncotarget; 2013 Jun; 4(6):911-22. PubMed ID: 23978789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis, binding and structure-affinity studies of new ligands for the microsomal anti-estrogen binding site (AEBS).
    Poirot M; De Medina P; Delarue F; Perie JJ; Klaebe A; Faye JC
    Bioorg Med Chem; 2000 Aug; 8(8):2007-16. PubMed ID: 11003145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. From tamoxifen to dendrogenin A: The discovery of a mammalian tumor suppressor and cholesterol metabolite.
    Silvente-Poirot S; de Medina P; Record M; Poirot M
    Biochimie; 2016 Nov; 130():109-114. PubMed ID: 27262406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Studies on the ligand specificity and potential identity of microsomal antiestrogen-binding sites.
    Watts CK; Sutherland RL
    Mol Pharmacol; 1987 May; 31(5):541-51. PubMed ID: 3553893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modifications of benzylphenoxy ethanamine antiestrogen molecules: influence affinity for antiestrogen binding site (AEBS) and cell cytotoxicity.
    Delarue F; Kedjouar B; Mésange F; Bayard F; Faye JC; Poirot M
    Biochem Pharmacol; 1999 Mar; 57(6):657-61. PubMed ID: 10037451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microsomal binding sites for antioestrogens in rat liver. Properties and detergent solubilization.
    Watts CK; Sutherland RL
    Biochem J; 1986 Jun; 236(3):903-11. PubMed ID: 3790095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiestrogen binding site and estrogen receptor mediate uptake and distribution of 4-hydroxytamoxifen-targeted doxorubicin-formaldehyde conjugate in breast cancer cells.
    Burke PJ; Kalet BT; Koch TH
    J Med Chem; 2004 Dec; 47(26):6509-18. PubMed ID: 15588086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis of 2-(p-chlorobenzyl)-3-aryl-6-methoxybenzofurans as selective ligands for antiestrogen-binding sites. Effects on cell proliferation and cholesterol synthesis.
    Teo CC; Kon OL; Sim KY; Ng SC
    J Med Chem; 1992 Apr; 35(8):1330-9. PubMed ID: 1573630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential effects of tamoxifen and analogs with nonbasic side chains on cell proliferation in vitro.
    Murphy LC; Sutherland RL
    Endocrinology; 1985 Mar; 116(3):1071-8. PubMed ID: 3971898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subcellular and extracellular localization of specific binding sites for triphenylethylene antiestrogens in human breast cancer.
    Gulino A; Vacca A; Modesti A; Screpanti I; Farina A; Frati L
    Biochem Pharmacol; 1986 Nov; 35(21):3863-70. PubMed ID: 3778510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resistance to tamoxifen with persisting sensitivity to estrogen: possible mediation by excessive antiestrogen binding site activity.
    Pavlik EJ; Nelson K; Srinivasan S; Powell DE; Kenady DE; DePriest PD; Gallion HH; van Nagell JR
    Cancer Res; 1992 Aug; 52(15):4106-12. PubMed ID: 1638522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.